US Stock MarketDetailed Quotes

Estrella Immunopharma (ESLA)

Watchlist
  • 1.840
  • -0.010-0.54%
Close Apr 10 16:00 ET
  • 1.760
  • -0.080-4.33%
Post 20:01 ET
78.50MMarket Cap-5.26P/E (TTM)

Estrella Immunopharma (ESLA) Income Statement

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2025
(Q4)Dec 31, 2025
(Q3)Sep 30, 2025
(Q2)Jun 30, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q4)Jun 30, 2024
(Q3)Mar 31, 2024
(Q2)Dec 31, 2023
(Q1)Sep 30, 2023
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
195.07%13.06M
-84.47%613.2K
922.54%4.8M
5.54M
2.1M
-60.17%4.43M
44.59%3.95M
-82.87%469.53K
-62.97%1.02M
-35.17%1.87M
Selling and administrative expenses
79.43%2.81M
38.48%587.79K
45.89%648.51K
--883.73K
--694.11K
136.49%1.57M
172.56%424.45K
277.66%444.53K
536.85%945.17K
394.92%1.39M
-General and administrative expense
79.43%2.81M
38.48%587.79K
45.89%648.51K
--883.73K
--694.11K
136.49%1.57M
172.56%424.45K
277.66%444.53K
536.85%945.17K
394.92%1.39M
Research and development costs
258.52%10.25M
-99.28%25.41K
16,510.57%4.15M
--4.66M
--1.41M
-72.65%2.86M
36.85%3.53M
-99.05%25K
-97.11%75.46K
-81.44%483.47K
Operating profit
-195.07%-13.06M
84.47%-613.2K
-922.54%-4.8M
-5.54M
-2.1M
60.17%-4.43M
-44.59%-3.95M
82.87%-469.53K
62.97%-1.02M
35.17%-1.87M
Net non-operating interest income expense
Other net income (expense)
Income before tax
-195.07%-13.06M
84.47%-613.2K
-922.54%-4.8M
-5.54M
-2.1M
60.17%-4.43M
-44.59%-3.95M
82.87%-469.53K
62.97%-1.02M
35.17%-1.87M
Income tax
1,230.16%838
-101.54%-25
0
850
13
63
1.63K
0
0
0
Net income
-195.09%-13.06M
84.48%-613.17K
-922.54%-4.8M
-5.54M
-2.1M
60.17%-4.43M
-44.65%-3.95M
82.87%-469.53K
62.97%-1.02M
35.17%-1.87M
Net income continuous Operations
-195.09%-13.06M
84.48%-613.17K
-922.54%-4.8M
---5.54M
---2.1M
60.17%-4.43M
-44.65%-3.95M
82.87%-469.53K
62.97%-1.02M
35.17%-1.87M
Minority interest income
Net income attributable to the parent company
-195.09%-13.06M
84.48%-613.17K
-922.54%-4.8M
-5.54M
-2.1M
60.17%-4.43M
-44.65%-3.95M
82.87%-469.53K
62.97%-1.02M
35.17%-1.87M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-195.09%-13.06M
84.48%-613.17K
-922.54%-4.8M
-5.54M
-2.1M
60.17%-4.43M
-44.65%-3.95M
82.87%-469.53K
62.97%-1.02M
35.17%-1.87M
Basic earnings per share
-191.67%-0.35
92.31%-0.01
-1,200.00%-0.13
-0.15
-0.06
61.99%-0.12
-67.53%-0.13
87.16%-0.01
61.69%-0.03
35.18%-0.0531
Diluted earnings per share
-191.67%-0.35
92.31%-0.01
-1,200.00%-0.13
-0.15
-0.06
61.99%-0.12
-67.53%-0.13
87.16%-0.01
61.69%-0.03
35.18%-0.0531
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Audit Opinions
Unqualified Opinion with Explanatory Notes
--
--
--
--
Unqualified Opinion with Explanatory Notes
--
--
--
--
(FY)Dec 31, 2025(Q4)Dec 31, 2025(Q3)Sep 30, 2025(Q2)Jun 30, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q4)Jun 30, 2024(Q3)Mar 31, 2024(Q2)Dec 31, 2023(Q1)Sep 30, 2023
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 195.07%13.06M-84.47%613.2K922.54%4.8M5.54M2.1M-60.17%4.43M44.59%3.95M-82.87%469.53K-62.97%1.02M-35.17%1.87M
Selling and administrative expenses 79.43%2.81M38.48%587.79K45.89%648.51K--883.73K--694.11K136.49%1.57M172.56%424.45K277.66%444.53K536.85%945.17K394.92%1.39M
-General and administrative expense 79.43%2.81M38.48%587.79K45.89%648.51K--883.73K--694.11K136.49%1.57M172.56%424.45K277.66%444.53K536.85%945.17K394.92%1.39M
Research and development costs 258.52%10.25M-99.28%25.41K16,510.57%4.15M--4.66M--1.41M-72.65%2.86M36.85%3.53M-99.05%25K-97.11%75.46K-81.44%483.47K
Operating profit -195.07%-13.06M84.47%-613.2K-922.54%-4.8M-5.54M-2.1M60.17%-4.43M-44.59%-3.95M82.87%-469.53K62.97%-1.02M35.17%-1.87M
Net non-operating interest income expense
Other net income (expense)
Income before tax -195.07%-13.06M84.47%-613.2K-922.54%-4.8M-5.54M-2.1M60.17%-4.43M-44.59%-3.95M82.87%-469.53K62.97%-1.02M35.17%-1.87M
Income tax 1,230.16%838-101.54%-25085013631.63K000
Net income -195.09%-13.06M84.48%-613.17K-922.54%-4.8M-5.54M-2.1M60.17%-4.43M-44.65%-3.95M82.87%-469.53K62.97%-1.02M35.17%-1.87M
Net income continuous Operations -195.09%-13.06M84.48%-613.17K-922.54%-4.8M---5.54M---2.1M60.17%-4.43M-44.65%-3.95M82.87%-469.53K62.97%-1.02M35.17%-1.87M
Minority interest income
Net income attributable to the parent company -195.09%-13.06M84.48%-613.17K-922.54%-4.8M-5.54M-2.1M60.17%-4.43M-44.65%-3.95M82.87%-469.53K62.97%-1.02M35.17%-1.87M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -195.09%-13.06M84.48%-613.17K-922.54%-4.8M-5.54M-2.1M60.17%-4.43M-44.65%-3.95M82.87%-469.53K62.97%-1.02M35.17%-1.87M
Basic earnings per share -191.67%-0.3592.31%-0.01-1,200.00%-0.13-0.15-0.0661.99%-0.12-67.53%-0.1387.16%-0.0161.69%-0.0335.18%-0.0531
Diluted earnings per share -191.67%-0.3592.31%-0.01-1,200.00%-0.13-0.15-0.0661.99%-0.12-67.53%-0.1387.16%-0.0161.69%-0.0335.18%-0.0531
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Audit Opinions Unqualified Opinion with Explanatory Notes--------Unqualified Opinion with Explanatory Notes--------
Market Insights
China Concept Stocks
View More
Middle East conflict spreads to the stock market! How should investors respond?
On April 12 local time, U.S. Vice President Vance stated that negotiations between the United States and Iran failed to reach an agreement, Show More